Pharmafile Logo

daclizumab

Commercial Execution Strategies During & After the Pandemic

Frank Armenante, Director of Commercial Execution at Novo Nordisk, discusses a range of topics, from the impact of COVID-19 on commercial operations and the digitization of Pharma to his leadership lessons...

Impetus Digital

- PMLiVE

FDA briefing documents back Biogen’s Alzheimer’s drug aducanumab

Documents show the efficacy data for the drug as being ‘exceptionally persuasive’

- PMLiVE

FDA sets November date for expert panel review of Biogen’s aducanumab

Advisory committee will review biologics license application for controversial therapy

- PMLiVE

Leadership change within Bedrock Group

Marie Little appointed Managing Director of Bedrock Healthcare Communications Limited

Bedrock Healthcare Communications

- PMLiVE

Vir Biotech plans to start mid-to-late stage study of COVID-19 antibody this month

Monoclonal antibody has neutralised SARS-CoV-2 virus in vitro

- PMLiVE

Biogen’s highly-anticipated Alzheimer’s drug wins FDA fast-track

Drug could become first treatment to reduce clinical decline in Alzheimer's

- PMLiVE

Biogen pays Denali $1bn upfront for Parkinson’s disease programme

Deal includes portfolio of small molecule LRRK2 inhibitors

- PMLiVE

AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies

Biotech company did not disclose the reason for the partnership's end

- PMLiVE

Roche pays $120m upfront for UCB’s anti-tau Alzheimer’s drug

Milestone payments could reach up to $2bn

- PMLiVE

Biogen raises full year guidance after beating Q2 expectations

Key drug franchises boost total revenues in the quarter

Biogen Idec building

Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3

Pivotal AHEAD 3-45 programme initiated this week

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links